Last reviewed · How we verify
Surgilube
Surgilube, developed by the University of California, San Diego, is a marketed product with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging the credibility and research capabilities of a leading academic institution. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Surgilube |
|---|---|
| Sponsor | University of California, San Diego |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Empathy Through Pain Control: Lidocaine Paracervical Block for IUD Placements (NA)
- Empathy Through Pain Control: Lidocaine Gel vs. Placebo Prior to IUD Placement (NA)
- Intraurethral Lidocaine After Endourology Procedures (PHASE3)
- Lidocaine Jelly for Pain Control During Mohs Surgery (PHASE4)
- Intracervical Lidocaine Gel for IUD Insertional Pain (NA)
- Lubricant Versus Lidocaine Gel for Pain Control During Urodynamics (NA)
- Double Blinded Randomized Trial Between Lidocaine And Plain Gel For Urethral Straight Catheterization And The Q-Tip Test (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Surgilube CI brief — competitive landscape report
- Surgilube updates RSS · CI watch RSS
- University of California, San Diego portfolio CI